Overview

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Giessen
Treatments:
Cladribine